Patanjali to launch ayurvedic drug for Covid-19, claims cure within 14 days
Balkrishna had earlier this month claimed that an Ayurvedic medicine developed by the company has been able to cure Covid-19 patients within 5-14 days
)
Explore Business Standard
Balkrishna had earlier this month claimed that an Ayurvedic medicine developed by the company has been able to cure Covid-19 patients within 5-14 days
)
Patanjali will launch the ayurvedic medicine for treating Covid-19 at Patanjali Yogpeeth in Haridwar on Tuesday.
"Proud launch of first and foremost evidence-based ayurvedic medicine for #corona contagion, #SWASARI_VATI, #CORONIL, is scheduled for tomorrow at 12 noon from #Patanjali Yogpeeth Haridwar," Acharya Balkrishna, Chief Executive Officer (CEO) of Patanjali, tweeted on Monday.
Balkrishna had earlier this month claimed that an Ayurvedic medicine developed by the company has been able to cure Covid-19 patients within 5-14 days.
"We appointed a team of scientists after Covid-19 outbreak. Firstly, the simulation was done and compounds were identified which can fight the virus and stop its spread in the body. Then, we conducted a clinical case study on hundreds of positive patients and we have got 100 per cent favourable results," Balkrishna said.
"After taking our medicine, COVID patients recovered in 5-14 days and then tested negative. So, we can say the cure for COVID is possible through Ayurveda. We are performing controlled clinical trials only. In the next 4-5 days, evidence and data will be released by us," he added.
The Patanjali CEO further said that people should practice Yoga, and keep oneself healthy through proper diet to boost the immune system.
With an increase of 14,821 new cases and 445 deaths, India's Covid-19 count crossed 4.25 lakh on Monday. The country has reported a total of 4,25,282 cases and 13,699 persons have died.
The Health Ministry said that 9,440 patients have been cured in the last 24 hours and the country's recovery rate has gone up to 55.77 per cent.
Already subscribed? Log in
Subscribe to read the full story →
3 Months
₹300/Month
1 Year
₹225/Month
2 Years
₹162/Month
Renews automatically, cancel anytime
Over 30 premium stories daily, handpicked by our editors


News, Games, Cooking, Audio, Wirecutter & The Athletic
Digital replica of our daily newspaper — with options to read, save, and share


Insights on markets, finance, politics, tech, and more delivered to your inbox
In-depth market analysis & insights with access to The Smart Investor


Repository of articles and publications dating back to 1997
Uninterrupted reading experience with no advertisements


Access Business Standard across devices — mobile, tablet, or PC, via web or app
First Published: Jun 23 2020 | 7:45 AM IST